Bigbear Pharmaceutical·Medication Guide

• Enasidenib Dosage and Administration: Medication Guidelines, Dosage Adjustments

  Enasidenib is indicated for adult patients with relapsed or refractory acute myeloid leukemia (AML) who have been diagnosed with an isocitrate dehydro···【Read More】

  Update: 2026-03-09Source: Haiou HealthViews: 117

• Instructions for Use of the Targeted Therapy Doptelet

  Avatrombopag (Doptelet) increases platelet production by mimicking the action of endogenous thrombopoietin (TPO), activating TPO receptors, and promot···【Read More】

  Update: 2026-03-09Source: Haiou HealthViews: 118

• Dosage and Administration of Avatrombopag (Doptelet): Medication Guidelines, Dosage Adjustment, Use

  Avatrombopag (Doptelet) has different dosages and precautions for patients with chronic liver disease and chronic immune thrombocytopenic purpura. It ···【Read More】

  Update: 2026-03-09Source: Haiou HealthViews: 116

• Detailed Product Information for Avatrombopag (Doptelet), a Targeted Therapy

  Avatrombopag (Doptelet) is an oral small-molecule thrombopoietin receptor agonist (TPO-RA) that effectively increases preoperative platelet levels in ···【Read More】

  Update: 2026-03-09Source: Haiou HealthViews: 119

• Side effects of avatrombopag (Doptelet): Serious adverse reactions, common side effects, and side ef

  When taking avatrombopag (Doptelet), serious side effects such as bleeding gums and nosebleeds, and abnormal weight gain or loss may occur; milder sid···【Read More】

  Update: 2026-03-09Source: Haiou HealthViews: 113

• FDA Approves Avatrombopag (Doptelet) for the Treatment of Patients with Chronic Liver Disease

  On May 21, 2018, the U.S. Food and Drug Administration (FDA) approved avatrombopag (Doptelet) tablets for the treatment of thrombocytopenia (low plate···【Read More】

  Update: 2026-03-09Source: Haiou HealthViews: 110

• FDA Approves Avatrombopag (Doptelet) for the Treatment of Chronic Immune Thrombocytopenic Pulmonary

  On June 27, 2019, the U.S. Food and Drug Administration (FDA) approved the expansion of the indication for avatrombopag (Doptelet) to include the trea···【Read More】

  Update: 2026-03-09Source: Haiou HealthViews: 114

• FDA Approves Avatrombopag (Doptelet) for the Treatment of Thrombocytopenia

  On July 25, 2025, the U.S. Food and Drug Administration (FDA) approved avatrombopag (Doptelet) for the treatment of thrombocytopenia in pediatric pati···【Read More】

  Update: 2026-03-09Source: Haiou HealthViews: 132

• Understanding the Risk of Bone Fractures and Heart Issues While on Entrectinib

  Entrectinib is a targeted anticancer drug primarily used to treat solid tumors and lymphomas carrying specific gene mutations. Common side effects inc···【Read More】

  Update: 2026-03-09Source: Haiou HealthViews: 121

• Understanding the Risk of Bone Fractures and Heart Issues While on Entrectinib

  Entrectinib is a targeted anticancer drug primarily used to treat solid tumors and lymphomas carrying specific gene mutations. Common side effects inc···【Read More】

  Update: 2026-03-09Source: Haiou HealthViews: 113

• Entrectinib Price in Different Countries

  The price of entrectinib fluctuates depending on the strength, purchase channel, and region. The original brand-name drug may be more expensive, while···【Read More】

  Update: 2026-03-09Source: Haiou HealthViews: 122

• Does Insurance Cover Entrectinib? A Guide to Prior Authorization and Reimbursement

  The price of entrectinib varies depending on the region, health insurance policy, dosage, and purchase channel. The specific monthly treatment cost ne···【Read More】

  Update: 2026-03-09Source: Haiou HealthViews: 113

• Where to Purchase Crizotinib

  IndicationsCrizotinib, also known as XALKORI, is indicated for the treatment of:ALK‑positive or ROS1‑positive metastatic non‑small cell lung cancer (N···【Read More】

  Update: 2026-03-09Source: Haiou HealthViews: 116

• Latest Price of Genuine Crizotinib

  Indications and Mechanism of ActionCrizotinib is indicated for patients with ALK‑positive locally advanced or metastatic non‑small cell lung cancer (N···【Read More】

  Update: 2026-03-09Source: Haiou HealthViews: 126

• FDA Approves Extended Duration of Prevymis for HSCT Patients at Risk of Late‑Onset Cytomegalovirus

  FDA Approval AnnouncementYesterday, the U.S. Food and Drug Administration (FDA) approved an extended duration of use for Prevymis (letermovir), from 1···【Read More】

  Update: 2026-03-09Source: Haiou HealthViews: 144